The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Abstract
Background Though selective serotonin reuptake inhibitors have revolutionized the field of psychiatry with demonstrated efficacy in affective and anxiety disorders with minimal side effects, norepinephrine-serotonin reuptake inhibitors may provide efficacy similar to tricyclic antidepressants without the adverse side effects associated with tricyclic antidepressants. Methods The affinity and selectivity of milnacipran, duloxetine, venlafaxine, citalopram, amitriptyline, and nortriptyline were determined for the human serotonin, norepinephrine, and dopamine transporters. Results Both milnacipran and duloxetine were potent inhibitors of serotonin and norepinephrine uptake. Unlike duloxetine and venlafaxine, milnacipran appears serotonin transporter selective in binding (ratio = 2.61) and norepinephrine transporter selective in uptake (ratio =.45). Conclusions Milnacipran's binding and uptake inhibition profile more closely resembles that of the tricyclic antidepressants than that of duloxetine. Whether these differences observed in vitro manifest themselves in vivo is not clear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DLX and MLN are serotonin (5HT) and norepinephrine (NE) reuptake inhibitors.”
From Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome (2010) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DLX has a 5:1 5HT/NE ratio and MLN has a 3:1 NE/5HT ratio.”
From Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome (2010) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 725
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Self-citationOwens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 518
Self-citationAnderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+ · Cited by 278
Moret, C., Charvéron, M., Finberg, J. P. M., Couzinier, J. P., & Briley, M. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90157-1 · Cited by 173
Turcotte, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00220-7 · Cited by 110
Béïque, J.-C., Lavoie, N., de Montigny, C., & Debonnel, G. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00241-6 · Cited by 107
Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine
Gilmor, M. L., Owens, M. J., & Nemeroff, C. B. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1702 · Cited by 87
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–182 of 182
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 12
3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
Avram, S. (2010) · Scientia Pharmaceutica · doi:10.3797/scipharm.0912-22 · Cited by 12
Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium
Bernstein, C., Albrecht, K. L., & Marcus, D. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.779670 · Cited by 12
Gastrointestinal and Hepatic Disease in Fibromyalgia
Schatz, R. A., & Moshiree, B. (2017) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2017.09.009 · Cited by 12
Orden, L. J. V., Dyke, P. M. V., Saito, D. R., Church, T. J., Chang, R., Smith, J. A. M., Martin, W. J., Jaw‐Tsai, S., & Stangeland, E. L. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.061 · Cited by 12
Dyck, B. P., Tamiya, J., Jovic, F., Pick, R. R., BRADBURY, M. J., O'Brien, J. L., Wen, J., Johns, M. S., Madan, A., Fleck, B. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8009537 · Cited by 11
Vorobeychik, Y., & Acquadro, M. A. (2008) · Journal of Musculoskeletal Pain · doi:10.1080/10582450802161960 · Cited by 11
Jaramillo, D. N., Millán, D., & Guevara‐Pulido, J. O. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106403 · Cited by 11
Mease, P. J., ZIMETBAUM, P. J., Duh, M. S., Vekeman, F., Guérin, A., Boerstoel-Streefland, M., Jiang, W., & Lefèbvre, P. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p391 · Cited by 11
Dual serotonin and noradrenaline reuptake inhibitors: Focus on their differences
Blier, P. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600645612 · Cited by 11
The effects of serotonin reuptake inhibitors on locomotor activity in gerbils
Prinssen, E. P. M., Ballard, T. M., Kolb, Y., & NICOLAS, L. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.005 · Cited by 10
Milnacipran Inhibits Oxaliplatin-Induced Mechanical Allodynia through Spinal Action in Mice
Andoh, T., Kitamura, R., & Kuraishi, Y. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00581 · Cited by 9
Dias, C. L., Bajerski, L., Rossi, R. C., Bergold, A. M., & Fröehlich, P. E. (2010) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.1000112 · Cited by 9
Absence of sibutramine effect on spontaneous anxiety in rats
Frassetto, S. S., Alves, I. O., Santos, M. M., Schmidt, A. E. S., Lopes, J. J., de Oliveira, P. A., Vinagre, A. S., & Pereira, P. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000400006 · Cited by 9
Morphy, R., & Ranković, Z. (2010) · doi:10.1002/9780470584170.ch5 · Cited by 9
Antidepressants and Risk of Type 2 Diabetes Mellitus
Kuo, H.-Y., Chen, H., Lee, C., Lee, H.-H., Kuo, C.-J., Hsu, C., Pan, C., Su, N., & Chu, C. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001228 · Cited by 9
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s11775 · Cited by 8
Yamamoto, M., Hirakata, H., & Toda, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1777975 · Cited by 11
Craine, T. J., Race, N. S., Kutash, L. A., Iouchmanov, A. L., Moschonas, E. H., O’Neil, D. A., Sunleaf, C. R., Patel, A., Patel, N., Grobengeiser, K. O., et al. (2022) · Journal of Neurotrauma · doi:10.1089/neu.2022.0289 · Cited by 7
Duloxetine Attenuated Morphine Withdrawal Syndrome in the Rat
Charkhpour, M., Jafari, R., Ghavimi, H., Ghanbarzadeh, S., & Parvizpur, A. (2013) · Drug Research · doi:10.1055/s-0033-1358728 · Cited by 8
Newer agents for the treatment of painful diabetic peripheral neuropathy
Freeman, R. L. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0047-7 · Cited by 7
Bagchi, S., Nozohouri, E., Ahn, Y., Patel, D., Bickel, U., & Karamyan, V. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010053 · Cited by 6
Hashimoto, T., Sakurai, D., Oda, Y., Hasegawa, T., Kanahara, N., Sasaki, T. G., Komatsu, H., Takahashi, J., Oiwa, T., Sekine, Y., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s95067 · Cited by 5
McConathy, J., Owens, M. J., Kilts, C. D., Malveaux, E., Votaw, J. R., Nemeroff, C. B., & Goodman, M. M. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.04.012 · Cited by 5
Self-citationWebster, M. (2015) · Mental Health Clinician · doi:10.9740/mhc.2015.11.284 · Cited by 4
Attention Deficit Hyperactivity Disorder
Marco, P., Maddalena, M., Bertella, S., Gatti, E., & Nobile, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00164-x · Cited by 5
Precision Medicine in Antidepressants Treatment
Tsermpini, E. E., Serretti, A., & Dolžan, V. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_654 · Cited by 4
Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
Miller, C. W. T., & Gallagher, K. E. (2016) · Case Reports in Psychiatry · doi:10.1155/2016/5472492 · Cited by 4
Antidepressant therapy with milnacipran and venlafaxine
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s11776 · Cited by 4
Shinkai, K., Yoshimura, R., Toyohira, Y., Ueno, S., Tsutsui, M., Nakamura, J., & Yanagihara, N. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.07.031 · Cited by 4
Milnacipran: recent findings in depression
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s11772 · Cited by 4
Raddad, E., Melhem, M., Sloan‐Lancaster, J., Miller, J. W., Wart, S. A. V., & Rubino, C. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.43 · Cited by 4
Zaazaa, A., Eldin, M. N., Din, S. F. G., Zeidan, A., Saleh, M. Y. M., Adel, A., & Shokr, M. (2023) · Basic and Clinical Andrology · doi:10.1186/s12610-023-00210-1 · Cited by 3
Pharmacogenomics and Psychopharmacology
Lapetina, D. L., Yang, E. H., Henriques, B. C., & Aitchison, K. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.007 · Cited by 3
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Komsuoglu, I. C., Mutlu, O., & Ulak, G. (2012) · InTech eBooks · doi:10.5772/37999 · Cited by 3
Chen, Z., Yang, J. H., & Skolnick, P. (2007) · Topics in medicinal chemistry · doi:10.1007/7355_2007_016 · Cited by 3
A new treatment option for fibromyalgia
Bennett, R. M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.48 · Cited by 3
Palmer, R. H., Periclou, A. P., & Banerjee, P. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10372551 · Cited by 6
Comparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors
Adachi, Y., Aleksić, B., & Ozaki, N. (2010) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.1.10 · Cited by 3
Traditional and Novel Possible Targets for Antidepressant Drugs
Palazidou, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-14021-6_2 · Cited by 3
Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder
Kamath, J., DeMartinis, N. A., & Handratta, V. D. (2007) · Future Neurology · doi:10.2217/14796708.2.4.361 · Cited by 3
Perez, J., Gonzalez, M., & Ramirez, S. (2024) · Specialty Journal of Pharmacognosy, Phytochemistry, and Biotechnology · doi:10.51847/rmgserramc
Morena, D., Colonna, S. S., Santurro, A., Scopetti, M., Tortorella, A., & Fineschi, V. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251406044 · Cited by 2
Ganoderma lucidum : An Emerging Nutritional Approach to Manage Depression
Jin, H., Aquili, L., Heng, B. C., Strekalova, T. V., Fung, M.-L., Tipoe, G. L., Kocabıçak, E., Blokland, A., Temel, Y., Lu, Z.-L., et al. (2025) · Food Reviews International · doi:10.1080/87559129.2025.2466456 · Cited by 3
New Treatment Options for Depression: A Primer for Internists
Byun, T. H., Chaliki, S. S., & Poole, K. G. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.012 · Cited by 2
Cada, D. J., Levien, T. L., & Baker, D. E. (2009) · Hospital Pharmacy · doi:10.1310/hpj4407-604 · Cited by 2
Dias, C. L., Rossi, R. C., Bajerski, L., & Fröehlich, P. E. (2011) · Dissolution Technologies · doi:10.14227/dt180311p47 · Cited by 2
Editorial Foreword - Milnacipran: recent findings in depression
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s11773 · Cited by 2
Davis, M. P. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_81-1 · Cited by 1
Life Threatening Acute Heart Failure in Two Young Adults Treated with Antidepressant Medication
Wikström, G. (2014) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000154 · Cited by 1
Inoue, T., Kitaichi, Nakagawa, Boku, S., Kato, Kusumi, & Koyama (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36906 · Cited by 1
Die klinische Anwendung von Milnacipran in Österreich und Deutschland
Hienert, M., Ritter, P. S., Bauer, M., Lanzenberger, R. R., & Kasper, S. F. (2019) · Nervenheilkunde · doi:10.1055/a-0828-3109 · Cited by 1
Psychopharmacological Treatment Issues in HIV/AIDS Psychiatry
Cozza, K. L., Wynn, G. H., Wortmann, G. W., Williams, S. G., & Rein, R. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780199392742.003.0042 · Cited by 1
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia
Leo, R. J. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.39
Gallagher, P., Mgh, P., Murphy, S. N., Gainer, V. S., & Churchill, S. E. (2011)
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · doi:10.3109/9781420084887-4
Milnacipran for Treatment of Fibromyalgia: A Review of Clinial Trials
Lee, K. E. (2010) · Korean Journal of Clinical Pharmacy
Maher, D. P., Shah, B. J., & Vorobeychik, Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-27447-4_19 · Cited by 1
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
Palaniyappan, L. K., Insole, L., & Ferrier, N. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.16.1.78
Current awareness in human psychopharmacology
(2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.567
Khojasteh, S. C., Wong, H., Zhang, D., & Hop, C. E. C. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-10691-0_2
Davis, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_81
Nakajima, K., Obata, H., Iriuchijima, N., & Saito, S. (2015) · NeuroTarget · doi:10.47924/neurotarget2015260
Chapter 19. Venlafaxine and Desvenlafaxine
Thase, M. E. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as19 · Cited by 1
Panday, S., Lang, B. J., Kapitanov, G., Subramanian, K., Klopp‐Schulze, L., Venkatakrishnan, K., Zutshi, A., & Alnaif, A. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3696
Wang, S.-W., Mi, W., Hao, X.-N., Liu, X., Wen, X., Zhao, M., Jiang, H., Wang, W., Li, T., Tan, Z.-L., et al. (2025) · Depression and Anxiety · doi:10.1155/da/6130764 · Cited by 2
An Investigation of the Anxiolytic Effects of Various Ssris and Snris Using ZebrafishPreprint
Shinokawa, K., Hattori, S., Miyauchi, M., Noguchi, N., Suda, A., Kishida, I., Nomoto, M., Hishimoto, A., & Asami, T. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5336861
Combining antidepressants to address treatment-resistant depression
Farrington, J., Kotara, S., & Nemeroff, C. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00012-8
Self-citationCampbell, A., Adamo, A., Bektik, E., Kosuri, Y., Karcher, C., Levine, D., Ramakrishnan, R., Grau, J. B., Levy, R. J., & Ferrari, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178954
Lau, D. H., Raj, S. R., & Gallagher, C. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.009
Morena, D., Lippi, M., Biso, L., Lucci, F., Turillazzi, E., Fineschi, V., & Scognamiglio, P. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01599-z
Metadata
- Authors
- Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J.
- Affiliations
- Emory University (US)
- Corresponding author
- Owens, Michael J
- ORCID
- Nemeroff, Charles B
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 55
- Issue
- 3
- Pages
- 320-322
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2113447800
- Cited by
- 178
- References
- 15
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 5 · 2015: 12 · 2014: 6 · 2013: 13 · 2012: 11
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- milnacipran, serotonin transporter, norepinephrine transporter, dopamine transporter, uptake inhibition, duloxetine, venlafaxine, citalopram, amitriptyline, nortriptyline, tricyclic antidepressants
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Milnacipran, Antidepressive Agents, Mental Disorders, Carrier Proteins, Cyclohexanols, Cyclopropanes, Humans, Membrane Glycoproteins, Nerve Tissue Proteins, Neurons, Norepinephrine, Serotonin, Thiophenes, Citalopram, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors, Membrane Transport Proteins, Symporters, Norepinephrine Plasma Membrane Transport Proteins, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
